Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dilated cardiomyopathy mutation in beta-cardiac myosin enhances actin activation of the power stroke and phosphate release.

PNAS nexus·2024
Same author

Dilated cardiomyopathy mutation in beta-cardiac myosin enhances actin activation of the power stroke and phosphate release.

bioRxiv : the preprint server for biology·2023
Same author

Dilated cardiomyopathy mutation E525K in human beta-cardiac myosin stabilizes the interacting-heads motif and super-relaxed state of myosin.

eLife·2022
Same author

Deafness mutation in the MYO3A motor domain impairs actin protrusion elongation mechanism.

Molecular biology of the cell·2021
Same author

Cardiomyopathy mutations impact the actin-activated power stroke of human cardiac myosin.

Biophysical journal·2021
Same author

Dilated cardiomyopathy mutation in the converter domain of human cardiac myosin alters motor activity and response to omecamtiv mecarbil.

The Journal of biological chemistry·2019
Same journal

A human-specific genetic modifier reconfigures large-scale cortical network dynamics underlying behavioral performance.

bioRxiv : the preprint server for biology·2026
Same journal

<i>Staphylococcus aureus</i> uses a eukaryotic-like uridyltransferase to make UDP-GlcNAc for cell wall synthesis.

bioRxiv : the preprint server for biology·2026
Same journal

Dynamic redistribution of eIF4F controls cap-dependent translation initiation.

bioRxiv : the preprint server for biology·2026
Same journal

When does additional information improve accuracy of RNA secondary structure prediction?

bioRxiv : the preprint server for biology·2026
Same journal

Normative brain-state trajectories reveal deviation from healthy aging in Alzheimer's disease.

bioRxiv : the preprint server for biology·2026
Same journal

Noradrenergic infraslow rhythm during sleep is the critical link between heart-rate dynamics and memory consolidation.

bioRxiv : the preprint server for biology·2026
See all related articles

Related Experiment Video

Updated: Jun 30, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

AZD5069 Inhibits Angiogenesis Without Cytotoxicity In Human Endothelial Cell Culture.

Carlo R Bartoli, Autumn Anthony, Rohini Desetty

    Biorxiv : the Preprint Server for Biology
    |June 29, 2026
    PubMed
    Summary
    This summary is machine-generated.

    AZD5069, a CXCR2 antagonist, effectively inhibited angiogenesis in human endothelial cells by reducing proliferation and migration without causing cell death. This suggests the CXCR2 pathway is a promising target for anti-angiogenesis therapies in various diseases.

    More Related Videos

    Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies
    09:03

    Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies

    Published on: June 30, 2023

    In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
    08:04

    In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

    Published on: May 11, 2021

    Related Experiment Videos

    Last Updated: Jun 30, 2026

    Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
    11:44

    Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

    Published on: March 30, 2019

    Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies
    09:03

    Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies

    Published on: June 30, 2023

    In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
    08:04

    In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

    Published on: May 11, 2021

    Area of Science:

    • Molecular Biology
    • Cell Biology
    • Pharmacology

    Background:

    • The CXCR2 receptor pathway is crucial for inflammatory and invasive angiogenesis in human diseases.
    • Targeting this pathway offers a potential therapeutic strategy for conditions involving aberrant blood vessel formation.

    Purpose of the Study:

    • To evaluate AZD5069, a selective CXCR2 antagonist, as an inhibitor of angiogenesis.
    • To assess the efficacy and safety of AZD5069 in human endothelial cell cultures.

    Main Methods:

    • Human endothelial cells (HUVECs, HAECs, HPAECs) were cultured and treated with varying concentrations of AZD5069.
    • Angiogenesis inhibition was measured by assessing endothelial cell proliferation (EdU uptake), migration (scratch assay), and tubule formation (Geltrex assay).
    • Cytotoxicity was evaluated using TUNEL assay for apoptosis and cyanine dye uptake for necrosis.

    Main Results:

    • AZD5069 significantly reduced endothelial cell proliferation, migration, and tubule formation in a dose-dependent manner.
    • No significant apoptosis or necrotic cell death was observed in AZD5069-treated cells.
    • These findings demonstrate AZD5069's anti-angiogenic properties without inducing cytotoxicity.

    Conclusions:

    • AZD5069 effectively inhibits angiogenesis in human endothelial cells without causing cytotoxicity.
    • The endothelial cell CXCR2 receptor pathway represents a novel target for anti-angiogenesis therapy.
    • AZD5069 shows potential clinical utility for treating cardiovascular, oncologic, and inflammatory diseases.